inner retina, for example, repulsive guidance cues regulate neurite lamination, adhesive cues maintain contact between appropriate synaptic partners, and proteins involved in transmitter release promote synaptic differentiation (Hoon et al., 2014) . Given such division of labor, one might have expected deletion of a2d4, which severs the link between pre-and postsynaptic organizers, to have limited consequences (e.g., misaligned synapses). Instead, Wang et al. (2017) show that loss of a2d4 affects the expression, localization, and alignment of many synaptic proteins; the adhesion of synaptic partners; and neurite lamination. As a result, all synaptic communication between rods and RBCs is lost and a2d4 KO mice cannot see in low light.
As with all exciting advances, the study of Wang et al. (2017) a2d subunits have now been shown to participate in complexes that align presynaptic calcium channels with postsynaptic transmitter receptors at two synapses: between inner hair cells and spiral ganglion neuron in the auditory system (Fell et al., 2016) and between rods and RBCs in the visual system (Wang et al., 2017) . Both of these are ribbon synapses of non-spiking presynaptic neurons, which support gradual changes in transmitter release. It is tempting to speculate that these synapses require particularly precise alignment of release sites and receptors to transmit continuously varying (i.e., analog) signals accurately. In this issue of Neuron, Gantz and Bean (2017) show that the endocannabinoid 2-arachidonoyl glycerol (2-AG) can directly alter the properties of native ion-channel Kv 4.3 and accelerate the pacemaker activity of rodent dopamine neurons. These findings are one of the first demonstrations of postsynaptic, cell-autonomous actions of endocannabinoids in the mammalian brain.
Undercover Power of Endocannabinoids
The endocannabinoid 2-AG, which is the focus of the study, and anandamide are the two main endogenous ligands of the cannabinoid receptors CB 1 and CB 2 (Pacher et al., 2006) . Endocannabinoids have pleiotropic functions within and outside the brain. They are involved in regulation of pain, sleep, eating, stress, immune response, inflammation, and liver function. Until now, CB 1 receptors were thought to mediate most of the effects of endocannabinoids in the brains of vertebrates, though CB 2 receptor expression in astrocytes, microglia, and other neurons has also been reported. Over a decade of research indicates that, within the brain, endocannabinoids produced by the postsynaptic neurons regulate the strength of synaptic connections and serve as retrograde signals that activate presynaptic G icoupled CB 1 receptors, suppressing synaptic transmission through the induction of short-and long-term synaptic plasticity (Lovinger, 2008) .
In a series of elegant, clever experiments, Gantz and Bean (2017) provide the strongest evidence to date that the bioactive lipid 2-AG, at low concentration, has cellular actions beyond activation of cannabinoid CB 1 and CB 2 receptors in mammals. These findings could explain why endocannabinoids are found in invertebrate species that do not express CB 1 or CB 2 orthologs (Lucanic et al., 2011) . Gantz and Bean show that activation of G q -coupled receptors expressed on dopamine neurons-such as metabotropic glutamate, orexin, and neurotensin receptors-triggered 2-AG synthesis through phospholipase C (PLC) activation and increased neuronal excitability in these neurons (Figure 1) .
The novel property of 2-AG as a modulator of native A-type potassium currents in midbrain dopamine neurons is congruent with previous findings made on a heterologous expression system (Barana et al., 2010; Oliver et al., 2004) . The postsynaptic actions of 2-AG also resemble the more well-known actions of arachidonic acid (AA) on these and other ion channels. AA is a metabolite of 2-AG and anandamide degradation, and it has no effect or potency on CB 1 and CB 2 receptors. AA is known to inhibit voltage-gated sodium and calcium channels as well as some types of G-protein-coupled, inwardly rectifying potassium channels (Meves, 2008) . AA potentiates M-type potassium channels, calcium-activated potassium channels, acid-sensing ion channels, the vanilloid type 1 receptor (TRPV-1) channels, and ligand-gated NMDA receptor currents.
Anandamide, the other major endocannabinoid, is also known to have targets other than CB receptors. Anandamide was shown to act both on potassium channels and on TRPV-1 (Zygmunt et al., 1999) and also to inhibit gap junctions (Venance et al., 1995) .
Since endocannabinoids and their metabolites can be readily produced on demand upon activation of PLC and other enzymes that are part of this pathway, these lipids might regularly influence neuronal activity though their direct actions on ion channels. Calcium influx is also sufficient to trigger endocannabinoid production in some neurons (Brenowitz et al., 2006) ; consequently, oscillation in intracellular calcium concentrations can act to further regulate endocannabinoid production and metabolism. Depending on the native composition of ion channels of each particular neuron, 2-AG and its metabolites could then either accelerate or decrease neuronal excitability.
To conclude, 2-AG is more than an endocannabinoid retrograde signal, and it has postsynaptic actions on the same cells that produce this bioactive lipid. More work is needed in order to determine how widespread and common these postsynaptic actions of 2-AG on A-type potassium channels and neuronal excitability are; this could also determine whether the postsynaptic effects of 2-AG could act in concert with its retrograde actions on presynaptic CB 1 receptors that lead to the long-lasting depression of synaptic strength.
Sixteen years ago, the first two reports of retrograde endocannabinoid signaling were published in this same journal (Kreitzer and Regehr, 2001; Wilson et al., 2001) . A brand-new field emerged in neuroscience, fueling our understanding of synaptic transmission and plasticity. In a similar fashion, we anticipate an explosion in the number of future studies reporting postsynaptic effects of 2-AG in other neurons throughout the brain and beyond. Endocannabinoid 2-AG is synthesized upon the activation of G q proteincoupled receptors (G q PCR), such as metabotropic glutamate, orexin, and neurotensin receptors. Through its canonical actions, 2-AG serves as a retrograde signal to activate presynaptic CB 1 receptors on excitatory and inhibitory synaptic terminals. Gantz and Bean (2017) show that novel postsynaptic actions of 2-AG on Kv 4.3 channels inhibit A-type potassium currents and enhance the excitability of dopamine neurons.
